Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence
DOI:
https://doi.org/10.15277/bjd.2020.247Keywords:
type 2 diabetes, mitochondria, imeglimin, glimins, tetrahydrotriazine, systematic review, meta-analysisAbstract
Imeglimin is a novel, first in-class, blood glucose-lowering agent which acts via a mitochondrial mechanism to enhance glucose-induced insulin secretion, decrease hepatic glucose output and increase glucose uptake by skeletal muscle. A systematic review and meta-analysis of randomised controlled clinical trials (RCTs) with imeglimin in adults with type 2 diabetes was undertaken. Of 45 articles identified, five were RCTs but, due to the format of the data, only three could be combined in a meta-analysis (total n=180 participants). A random-effects model found that imeglimin 1500 mg twice daily as monotherapy and add-on to metformin or sitagliptin was associated with reductions of HbA1c by −0.63% (95% CI −0.84 to −0.42) (−6.6 mmol/mol, 95% CI −8.8 to −4.4) and reductions of fasting plasma glucose by −0.52 mmol/L (95% CI −0.80 to −0.24) compared with placebo. Adverse events were minimal, mostly gastrointestinal, and without hypoglycaemia. It is concluded that imeglimin displays promising improvements in HbA1c and fasting plasma glucose and is generally well tolerated.References
DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19
Vial G, Chauvin M-A, Bendridi N, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 2015;64:2254–64. https://doi.org/10.2337/db14-1220
Patti M-E, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010;31:364–95. https://doi.org/10.1210/er.2009-0027
Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664−71. https://doi.org/10.1056/NEJMoa031314
Li J, Shirakawa, Y, Togashi T, et al. Effects of imeglimin on insulin secretion, beta-cell proliferation, or apoptosis in mouse islets. J Diabetes Invest 2018;9:12. https://doi.org/10.1111/jdi.12937
Pacini G. Mari A, Fouqueray P, et al. Imeglimin increases glucose-dependent insulin secretion and improves beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:541−5. https://doi.org/10.1111/dom.12452
Hallakou-Bozec S, Kergoat M, Bolze S, Lebovitz HE. Imeglimin preserves beta cell function and mass in male zucker diabetic fatty rats. Endocr Pract 2017; 23:1. https://d1io3yog0oux5.cloudfront.net/_938fdfc18803a883031931f148c6cae6/poxelpharma/db/419/2331/file/2016-11-17_WCIRDC+Imeglimin+beta+cell+function+and+mass+Final.pdf
Lablanche S, Tubbs E, Cottet-Rousselle C, et al. Imeglimin protects INS-1 cells and human islets against high glucose- and high fructose-induced cell death by inhibiting the mitochondrial PTP opening. Diabetes 2018;67(Suppl 1):81-OR. https://doi.org/10.2337/db18-81-OR
Detaille D, Vial G, Borelet A-L, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discovery 2016;2:15072. https://doi.org/10.1038/cddiscovery.2015.72
Lachaux M, Nicol L, Hamzaou M, et al. Imeglimin protects from diabetic cardiomyopathy in the obese zucker rat. Diabetes 2017;66(Suppl 1):2054-P.
Lachaux M, Souille M, Remy-Jouet I, et al. Acute imeglimin treatment improves metabolic syndrome-related cardiac and coronary endothelial dysfunction in the zucker fa/fa rat. Eur Heart J 2018;39:484−5.
Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 2012;14:852−8. https://doi.org/10.1111/j.1463-1326.2012.01611.x
Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2013;36:565−68. https://doi.org/10.2337/dc12-0453
Fouqueray P, Pirags V, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care 2014;37:1924−30. https://doi.org/10.2337/dc13-2349
Dubourg J, Ueki K, Watada H, et al. Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial. Diabetologia 2017;60(Suppl 1):843.
Poxel Pharma. Poxel and Sumitomo Dainippon Pharma announce positive top-line results for imeglimin phase 3 trial (TIMES 1) in Japan for the treatment of type 2 diabetes. 9 April 2019. https://www.poxelpharma.com/en_us/news-media/press-releases/detail/117/poxel-and-sumitomo-dainippon-pharma-announce-positive (accessed 23 March 2020).
Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther 2015;98:170−84. https://doi.org/10.1002/cpt.144
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
